# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-266989
Filing Date
2025-11-05
Accepted
2025-11-05 16:16:42
Documents
71
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | aldx-20250930.htm iXBRL | 10-Q | 2319959
2 | EX-31.1 | aldx-ex31_1.htm | EX-31.1 | 18225
3 | EX-31.2 | aldx-ex31_2.htm | EX-31.2 | 18254
4 | EX-32.1 | aldx-ex32_1.htm | EX-32.1 | 14159
5 | GRAPHIC | img131814069_0.jpg | GRAPHIC | 101648
| Complete submission text file | 0001193125-25-266989.txt |  | 8156312

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | aldx-20250930.xsd | EX-101.SCH | 967718
74 | EXTRACTED XBRL INSTANCE DOCUMENT | aldx-20250930_htm.xml | XML | 1265636

Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 251454252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)